当前位置: 首页 >> 检索结果
661. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.
作者: M D Feher.;A L Hepburn.;M B Hogarth.;S G Ball.;S A Kaye.
来源: Rheumatology (Oxford). 2003年42卷2期321-5页
To assess the short-term urate-lowering effect of fenofibrate in men on long-term allopurinol therapy for hyperuricaemia and gout.
662. A randomized double-blind pilot study comparing Doloteffin and Vioxx in the treatment of low back pain.
This randomized, double-dummy, double-blind pilot study of acutely exacerbated low back pain was aimed to inform a definitive comparison between Doloteffin, a proprietary extract of Harpagophytum, and rofecoxib, a selective inhibitor of cyclo-oxygenase-2 (COX-2).
663. The development and evaluation of a drug information leaflet for patients with rheumatoid arthritis.
To develop and assess the effectiveness of a drug information leaflet (DIL) for D-penicillamine (DPA) and determine whether additional verbal information provides enhanced benefit.
664. Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis.
Keliximab studies have provided evidence of the therapeutic potential of a non-depleting CD4 monoclonal antibody (mAb) in the treatment of rheumatoid arthritis (RA). Clenoliximab, an immunoglobulin G4 derivative of keliximab, has substantially reduced potential to deplete CD4 cells. In initial studies of clenoliximab, we investigated the hypothesis that the decrease in cell surface CD4 is the result of antibody-mediated stripping from the cell surface.
666. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study.
作者: M Breban.;E Vignon.;P Claudepierre.;V Devauchelle.;D Wendling.;E Lespessailles.;L Euller-Ziegler.;J Sibilia.;A Perdriger.;M Mezières.;C Alexandre.;M Dougados.
来源: Rheumatology (Oxford). 2002年41卷11期1280-5页
To evaluate the efficacy and safety of a loading regimen of the anti-tumour necrosis factor alpha (TNF-alpha) antibody infliximab in predominantly axial severe ankylosing spondylitis (AS).
667. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study.
To compare the efficacy and safety of intra-articular injections of two different hyaluronan preparations and placebo in patients with knee osteoarthritis.
668. Measuring the nutritional status of children with juvenile idiopathic arthritis using the bioelectrical impedance method.
To assess the nutritional status of children with juvenile idiopathic arthritis (JIA) using anthropometric measurements and bioelectrical impedance.
669. Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial.
作者: E H S Choy.;G S Panayi.;P Emery.;S Madden.;F C Breedveld.;M C Kraan.;J R Kalden.;A Rascu.;J C C Brown.;N Rapson.;J M Johnston.
来源: Rheumatology (Oxford). 2002年41卷10期1142-8页
Results of an earlier open-label pilot study showed that 4162W94 was a relatively non-depleting anti-CD4 monoclonal antibody that induced >80% down-modulation of CD4 molecules from the surface of T lymphocytes. This placebo-controlled repeat-cycle study was conducted in active rheumatoid arthritis (RA) patients to determine the duration of CD4 blockade required to achieve lasting clinical benefit.
670. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial.
作者: E H S Choy.;B Hazleman.;M Smith.;K Moss.;L Lisi.;D G I Scott.;J Patel.;M Sopwith.;D A Isenberg.
来源: Rheumatology (Oxford). 2002年41卷10期1133-7页
Biological products that neutralize tumour necrosis factor alpha (TNF-alpha) are beneficial in rheumatoid arthritis (RA). We studied the effects of CDP870, a novel anti-TNF-alpha antibody fragment modified to obtain a prolonged plasma half-life ( approximately 14 days).
671. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients.
作者: P Bartolucci.;J Ramanoelina.;P Cohen.;A Mahr.;P Godmer.;C Le Hello.;L Guillevin.
来源: Rheumatology (Oxford). 2002年41卷10期1126-32页
Evidence indicates that tumour necrosis factor (TNF) is a major agent in the pathogenesis of vasculitis. We studied the short-term effect of anti-TNF-alpha antibody in systemic vasculitis patients refractory to steroids and immunosuppressive agents.
672. The use of surgery and yttrium 90 in the management of extensive and diffuse pigmented villonodular synovitis of large joints.
作者: S Shabat.;Y Kollender.;O Merimsky.;J Isakov.;G Flusser.;M Nyska.;I Meller.
来源: Rheumatology (Oxford). 2002年41卷10期1113-8页
The surgical treatment of extensive diffuse pigmented villonodular synovitis (PVNS) of large joints alone is unsatisfactory, with high rates of local recurrence. Post-synovectomy adjuvant treatment with external beam radiation therapy or intra-articular injection of yttrium 90 (90Y) yielded better results. We report our experience with 10 cases treated with debulking surgery followed by intra-articular injection of 90Y.
673. Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trial.
作者: G F Ferraccioli.;R Assaloni.;E Di Poi.;E Gremese.;G De Marchi.;M Fabris.
来源: Rheumatology (Oxford). 2002年41卷10期1109-12页
To assess the possible clinical and biological rescue of rheumatoid arthritis (RA) in 16 patients who were still active despite intensive combination therapy after receiving infliximab following the Anti-Tumour necrosis factor Trial in Rheumatoid Arthritis with Concomitant Therapy (ATTRACT) schedule.
674. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis.
作者: K Gottesdiener.;T Schnitzer.;C Fisher.;B Bockow.;J Markenson.;A Ko.;L DeTora.;S Curtis.;L Geissler.;B J Gertz.; .
来源: Rheumatology (Oxford). 2002年41卷9期1052-61页
To evaluate the clinical efficacy and tolerability of etoricoxib in the treatment of osteoarthritis (OA) of the knee and define the clinically active dose range for further clinical trials.
675. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen.
作者: W Bensen.;A Weaver.;L Espinoza.;W W Zhao.;W Riley.;B Paperiello.;D P Recker.
来源: Rheumatology (Oxford). 2002年41卷9期1008-16页
To compare the efficacy of the COX-2 specific inhibitor valdecoxib with the conventional NSAID naproxen and placebo in treating rheumatoid arthritis (RA).
676. The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database.
A primary therapeutic goal in rheumatoid arthritis (RA) is to reduce functional disability. The recent introduction of several new drugs for RA creates a need for readily assessing the effectiveness of therapy. Because the consistent use of disease-modifying anti-rheumatic drugs (DMARDs) reduces long-term disability, we analysed the large database of 1817 RA patients from leflunomide trials to assess if changes in the Health Assessment Questionnaire (HAQ) can measure the effectiveness of RA therapy.
677. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years.
作者: G F Ferraccioli.;E Gremese.;P Tomietto.;G Favret.;R Damato.;E Di Poi.
来源: Rheumatology (Oxford). 2002年41卷8期892-8页
To evaluate two monotherapies followed by step-up combination therapy with two or three complementary drugs in active rheumatoid arthritis (RA) in comparison with sulphasalazine (SSZ) alone.
678. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents.
作者: M Y Karim.;P Alba.;M-J Cuadrado.;I C Abbs.;D P D'Cruz.;M A Khamashta.;G R V Hughes.
来源: Rheumatology (Oxford). 2002年41卷8期876-82页
Mycophenolate mofetil (MMF) is an immunosuppressive drug widely used in solid organ transplantation, and it may play an increasing role in autoimmune disease. MMF has been introduced as a novel immunosuppressive agent in systemic lupus erythematosus (SLE), often in patients intolerant of or resistant to conventional immunosuppressive regimens.
679. Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density.
作者: N J Minaur.;D Kounali.;S Vedi.;J E Compston.;J N Beresford.;A K Bhalla.
来源: Rheumatology (Oxford). 2002年41卷7期741-9页
To determine the effect of methotrexate (MTX) on bone mineral density (BMD) in rheumatoid arthritis (RA).
680. Usefulness of basal and pilocarpine-stimulated salivary flow in primary Sjögren's syndrome. Correlation with clinical, immunological and histological features.
作者: J Rosas.;M Ramos-Casals.;J Ena.;M García-Carrasco.;J Verdu.;R Cervera.;J Font.;O Caballero.;M Ingelmo.;E Pascual.
来源: Rheumatology (Oxford). 2002年41卷6期670-5页
To examine salivary function in patients with primary Sjögren's syndrome (SS) by assessing unstimulated and stimulated flows using 5 mg of pilocarpine in a 5% solution, in order to define their clinical usefulness in the evaluation of xerostomia in patients with primary SS as well as to identify those factors related to the increase in salivary flow after pilocarpine stimulation.
|